NEWS

Targovax ASA: Fourth quarter and full year 2016 results

Oslo, Norway, 16 February 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).

Photocure - full year report

Oslo Cancer Cluster member Photocure ASA reported that full year 2016 revenues ended at NOK 143.6 million (134.7). Photocure targets revenues from the US operations to quadruple to a range of USD 15 million by 2020.
War on Cancer Nordics

The Economist & Oslo Cancer Cluster: War on Cancer Nordics

Oslo Cancer Cluster is proud to be partner of the Economist Events War On Cancer Nordics. The event will gather leaders in oncology from the Nordic region and beyond, to discuss the region’s primary challenges in cancer care and control.

Oncoinvent closes $ 25 Million Private Placement

Our portfolio company Oncoinvent announced today the closing of a 210 MNOK (approx. 25 MUSD) private placement of ordinary shares. Financing will support development of Radspherin™, a novel radiotherapeutic treatment for peritoneal carcinomatosis.

Targovax with full year report

Oslo Cancer Cluster member Targovax will announce its fourth quarter and full year 2016 results on Thursday, 16 February 2017.